Denka Company (4061) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
7 Jan, 2026Executive summary
Net sales for 1H FY2024 rose 4.0% year-over-year to ¥199.1B, but operating income declined to ¥9.4B, down ¥1.1B YoY yet above forecast; net income was ¥3.4B, down ¥3.2B YoY and ¥0.6B below forecast.
Comprehensive income decreased 28.5% year-over-year to ¥13,579 million.
Key earnings recovery drivers include measures in the chloroprene rubber business, strategies for Electronics & Innovative Products, and cost reductions.
Financial highlights
Operating margin for 1H FY2024 was 4.7%, down from 5.5% YoY but above the initial forecast.
Ordinary income was ¥5.6B, down ¥2.5B YoY but ¥0.6B above forecast.
Basic earnings per share for the six months was ¥39.14, down from ¥76.09 YoY.
Dividend forecast remains at ¥100/share, with a 96% total return ratio.
Outlook and guidance
FY2024 full-year sales forecast is ¥420B, up ¥30.7B YoY; operating income forecast is ¥18B, up ¥4.6B YoY.
Ordinary profit is forecast at ¥12B, a 119.2% increase YoY; profit attributable to owners of parent is expected to decline 24.7% to ¥9B.
No change to initial full-year forecasts; impact of fundamental measures in the chloroprene rubber business not yet factored in.
Basic earnings per share for the full year is forecast at ¥104.44.
Dividend policy aims to maintain or increase dividends with a total return ratio of 50% over eight years.
Latest events from Denka Company
- Net income surged on asset sales despite lower sales, operating income, and DPE suspension.4061
Q1 202617 Mar 2026 - Mission 2030 Phase 2 targets record earnings, portfolio transformation, and sustainability.4061
Investor presentation27 Feb 2026 - Operating and net income surged despite lower sales, led by semiconductors and cost controls.4061
Q3 20266 Feb 2026 - Profits rose in 1H FY2025, with stable profit guidance and DPE losses offset by asset sales.4061
Q2 202610 Nov 2025 - Strong profit growth continues, but US regulatory risks for chloroprene rubber remain.4061
Q1 202513 Jun 2025 - Profit rebound is forecast after a net loss from extraordinary DPE-related losses.4061
Q4 20256 Jun 2025 - Sales up, profits down; forecasts and dividend unchanged amid regulatory risks.4061
Q3 20255 Jun 2025